First Patient Dosed in Phase III ProstACT GLOBAL Study of Antibody-based Prostate Cancer Therapy Candidate, TLX591

[ad_1] MELBOURNE, Australia, Nov. 12, 2023 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s Phase III…

Purdue Ventures invests in antibody-based cancer therapeutics company

[ad_1] TRIO Pharmaceuticals enhances the body’s immune system to effectively attack cancers WEST LAFAYETTE, Ind. – Purdue Ventures, which manages three funds to support Purdue University-connected startups, has invested $250,000…